AEGiS-ATN: New Guidelines for Avoiding Heart Disease by Managing High Cholesterol, Triglycerides, or Related Problems in HIV

Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.

New Guidelines for Avoiding Heart Disease by Managing High Cholesterol, Triglycerides, or Related Problems in HIV

AIDS TREATMENT NEWS Issue #394, September 12, 2003
John S. James

On September 1, 2003, the Infectious Disease Society of America (IDSA) released new guidelines for treating dyslipidemia (blood fat and some related disorders) in persons with HIV. These guidelines were prepared by a team of clinical scientists on the Cardiovascular Subcommittee of the AIDS Clinical Trials Group (ACTG), who updated preliminary recommendations published in 2000. These guidelines also reflect the updated cholesterol guidelines for the general public, which were published in 2001. The result is an authoritative (for 2003) and practical document filled with useful suggestions and advice. The new guidelines, 11 pages of text plus 147 references, were written mainly for physicians.

From the executive summary:

"We recommend that HIV-infected adults undergo evaluation and treatment on the basis of NCEP ATP III guidelines [National Cholesterol Education Project -- Adult Treatment Panel III] for dyslipidemia, with particular attention to potential drug interactions with antiretroviral agents and maintenance of virologic control of HIV infection. When drugs become necessary, we recommend as initial therapy pravastatin or atorvastatin for elevated low-density lipoprotein cholesterol levels and gemfibrozil or fenofibrate when triglyceride concentrations exceed 500 mg/dL."

Basically these guidelines apply the NCEP standards for reducing cardiovascular [heart and blood-vessel] disease risk for the general public, to people with HIV. There are a number of HIV- specific considerations, for example avoiding interactions of lipid-lowering drugs with antiretrovirals. Perhaps even more than in the general population, lifestyle changes such as diet and exercise (and of course quitting smoking) are recommended before lipid-lowering drugs, except in urgent cases.

The new guidelines review the following topics:

Evidence that certain antiretrovirals cause more lipid problems than others;
Possibilities of switching antiretrovirals;
Studies of the risk of cardiovascular disease in persons with HIV, using the NCEP to help decide about lifestyle changes and lipid-lowering drugs;
Therapeutic use of niacin to help correct cholesterol levels, or fish oils to reduce triglycerides, which may be tried in some cases;
When to refer a patient to an expert in treating dyslipidemia in persons with HIV;
Drug interactions, including certain lipid-lowering drugs to avoid because they can interact dangerously with antiretrovirals.

The guidelines were published in Clin Infect Dis. 2003 Sep 1;37(5):613-27. They are also available at the Web site of NATAP, the National AIDS Treatment Advocacy Project

030912
ATN39404

Copyright © 2003 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .